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Epitope mappingThe transmembrane envelope (TM) proteins of retroviruses are used as antigen in diagnostic immunoassays
and they represent a conserved target for neutralizing antibodies. To analyze the situation in infections with
the feline foamy virus (FFV), its recombinant TM protein was produced and used for ELISA and Western blot
analyses. Screening sera from 404 German cats showed that 39% reacted against the TM protein, the same
infection rate was determined using the Gag protein. Epitope mapping showed antibodies against the
membrane proximal external region (MPER) of the TM protein in the sera from infected cats, but attempts to
induce neutralizing antibodies by immunization with the recombinant TM protein failed. This is the ﬁrst
report demonstrating that the TM protein of the FFV is highly immunogenic and valuable for serological
screening. Similar to HIV-1, but in contrast to different gammaretroviruses, immunization with the TM
protein of FFV did not induce neutralizing antibodies.l rights reserved.© 2011 Elsevier Inc. All rights reserved.Introduction
The retroviral transmembrane envelope (TM) proteins play an
essential role during infection and thus their general structure is
highly conserved. They are composed of a fusion peptide at the N-
terminal end, an N-terminal helical region (NHR), a C-terminal helical
region (CHR) and the membrane-spanning domain (MSD) (Chan
et al., 1997). After insertion of the fusion peptide into the cellular
membrane and due to an interaction of both helical regions, the TM
proteins trigger the fusion of the cellular and viral membranes and
infection of the cells can occur (Melikyan, 2008). The TM proteins of
orthoretroviruses, e.g., gammaretroviruses and lentiviruses, including
the human immunodeﬁciency virus HIV-1, are well studied. They
contain an immunodominant cystein–cystein (Cys–Cys) loop be-
tween NHR and CHR with three Cys in the case of gammaretroviruses
and two Cys in the case of HIV-1. Sincemost of the infected individuals
produce antibodies against the TM protein, especially against the Cys–
Cys loop (Gnann et al., 1987; Denner et al., 1994), these proteins are
used for diagnostic purposes (Eberle et al., 1997;Manocha et al., 2003;
Greenwald et al., 2006). The TM protein gp41 of HIV-1 and the TM
protein p15E of different gammaretroviruses including the porcineendogenous retrovirus (PERV), the feline leukemia virus (FeLV) and
the Koala retrovirus (KoRV) are also the target for broadly
neutralizing antibodies which recognize epitopes located in the
membrane proximal external region (MPER) of their TM protein
(Muster et al., 1993; Stiegler et al., 2001; Fiebig et al., 2003, 2006;
Langhammer et al., 2005, 2006).
The TM proteins of the foamy viruses (FVs), which belong to the
sub-family of Spumaretrovirinae, differ signiﬁcantly from that of the
orthoretroviruses (Lindemann and Goepfert, 2003). They are larger
(gp48 in comparison with gp41 of HIV-1 and p15E of gammare-
troviruses, the last is not glycosylated), contain seven to eight
cysteines in case of the feline and primate FV (FFV and PFV) and
have an unusually prolonged central domain between their NHR
and CHR that distinguishes the TM of FVs from that of all other
retroviruses (Wang and Mulligan, 1999). FFV and PFV persistently
infect cats and primates including man, respectively, however in
contrast to the HIV-1, to the feline immunodeﬁciency virus (FIV)
and to FeLV, no pathological consequences of FV infections are
currently known (Linial, 2000; Alke et al., 2000). In previous
reports, the prevalence of FFV in wild and household cats ranged
from 33% to 70% depending on the method used and the geographic
region analyzed: ﬁrst data were obtained in a small group of
animals in Italy, 10 out of 11 cats infected with FIV, six out of nine
animals infected with FeLV and three out of 11 uninfected cats were
positive for FFV (Bandecchi et al., 1992). FFV was found in 33% of 30
wild cats trapped in Scotland (Daniels et al., 1999), in 53% of 201
Fig. 1. Expression, puriﬁcation and characterization of the TM protein of FFV. (A) Schematic presentation of the envelope protein of FFV containing the envelope leader protein (Elp),
the surface envelope protein (SU), the transmembrane envelope protein (TM) and furin cleavage sites indicated by arrows. The TM protein is further characterized by the fusion
peptide (FP) and the membrane spanning domain (MSD). The ectodomain of the TM protein was cloned with a GST and His tag, the arrow indicates the factor Xa cleavage site used
for the removal of the GST residue. (B) Characterization of the puriﬁed TM protein by SDS-PAGE and a Western blot assay using anti-His tag antibodies. The arrow indicates the TM
protein with a predicted molecular weight of 68 kDa.
334 M. Mühle et al. / Virology 412 (2011) 333–340Australian cats (Winkler et al., 1997), in 57% of a larger group of
Australian domestic cats (Winkler et al., 1999) and in 36% of
domestic cats from Switzerland (Romen et al., 2006). The infection
rate in German cats is still unknown. Although predominantly
immunological assays were used to study the prevalence of FV
infections, the immune response against the TM proteins was not
yet investigated. In this report we describe the expression,
puriﬁcation and immunological properties of the FFV TM protein
and its usage in a newly established ELISA for screening for FFV
infection in German cats. Using TM and Gag protein ELISA data, the
prevalence of FFV infection in cats in Germany was determined for
the ﬁrst time. Furthermore, we screened for neutralizing antibodies
in the sera from FFV positive cats. We show that epitopes targeted
by cat sera are similarly located as conserved epitopes recognized
by antibodies neutralizing gammaretroviruses or HIV-1. However,
attempts to induce antibodies neutralizing FFV in immunization
studies with the recombinant TM in a goat and rats were not
successful. This is similar to the situation with HIV-1 but in contrast
to the situation with gammaretroviruses, where neutralizing
antibodies were easily induced.
Results
Expression and puriﬁcation of recombinant TM protein
In order to express the TM protein of the FFV-FUV7 isolate, an
expression plasmid was generated fusing the codon-optimized
sequence of the ectodomain of the FFV TM protein to a glutathion
S-transferase (GST) and a C-terminal His tag (Fig. 1A) in the
prokaryotic expression vector pGEX-KG (Guan and Dixon, 1991).
Testing several other vector systems and tags, this was the only
construct to stably express the full-length protein. Since initialFig. 2. Screening of cat sera for antibodies against FFV. (A) Representative results of an ELIS
status; the calculation of the cut off is described in the text. (B) Testing of the same sera in a
1:100, in the Western blot assay 1:1000.expression levels were low, a systematic optimization of the
expression conditions using a 96-deep well expression screen was
performed. Most suitable bacterial strains, media, IPTG concentra-
tions and temperatures were selected (Mühle et al., in preparation).
Since even under mildest expression conditions most of the protein
was found expressed in inclusion bodies, resolubilization and
binding to the NiNTA-afﬁnity matrix was performed under
denaturing conditions followed by a gradual replacement of the
denaturant during the washing steps and subsequent elution. The
puriﬁed protein had a purity of about 95% and was recognized by
anti-His antibodies (Fig. 1B) and anti-GST antibodies (not shown).
The produced protein was used in ELISAs, Western blot assays and
for the immunization of a goat and rats described in this study.ELISA setup and screening of cat sera for antibodies against the
TM protein
To investigate whether naturally infected cats produce anti-
bodies speciﬁc for FFV TM, an ELISA was set up using the puriﬁed
TM protein and optimal conditions including blocking reagents and
antigen concentrations. Low background reactivity was achieved
blocking with PBS containing 1% dried skim milk and 0.05% Tween
20; 200 ng TM protein per well was selected as standard antigen
concentration and a serum dilution of 1:100 was chosen for all
assays. In an initial screen, 261 cat sera with unknown infection
status were investigated (Fig. 2A). As positive control, serum from
goat 348 immunized with the FFV TM protein, as negative control
the corresponding preimmune serum were used. 107 (41%) of the
sera reacted positive in the ELISA with the TM protein. The ELISA
results were conﬁrmed in a Western blot assay using the same
recombinant TM protein (Fig. 2B).A using the TM protein and the sera from cats with unknown serological FFV infection
Western blot assay using the same TM protein. The sera used in the ELISA were diluted
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Bet ELISA
To evaluate the TM protein based assay, the same sera were
tested in well-established ELISA based on the Gag and the Bet
proteins of FFV as described previously (Romen et al., 2006). 39% of
the sera were positive for Gag and 33% for Bet (Bleiholder et al.,
submitted). Comparison of all three assays showed a clear
correlation between the sera positive for antibodies against the
TM protein and the sera positive for antibodies against the Gag and
Bet proteins. ELISA results were conﬁrmed in Western blot assays
using FFV-infected CRFK cells as antigen (Bleiholder et al.,
submitted). The cut off in the ELISA using the FFV TM protein
was calculated using twice the mean value plus three standard
deviations of 100 Gag-negative sera. Using this threshold, nine sera
were positive for TM only. In addition, two sera showed ELISA
reactivity against Gag (Fig. 3A) and Bet (not shown) but not the TM
protein (Fig. 3A). Four of the nine sera positive for TM only were
conﬁrmed to be positive by Western blot analyses using recombi-
nant TM protein, but none of these sera showed the characteristic
52 and 48 kDa Gag pattern in the Western blot assay using antigens
from the FFV-infected cells (Fig. 3). A Western blot analysis of one
of these four sera (serum 34713) is shown in Fig. 3B. Since the
ELISA results of the ﬁve remaining sera were not conﬁrmed by
Western blot testing, these cats were considered not to be infected.
Of the two sera positive only for Gag and Bet, both were positive in
Western blots using FFV-infected cells, but not for the TM protein inFig. 3. Conﬁrmatory tests of the sera recognizing only FFV TM protein or only FFV Gag. (
corresponding cut offs are indicated. Below, the results of the Western blot analyses of the s
antigen are shown; (+) indicates a positive result, (−) a negative result in theWestern blot
an infected cat (+) and a negative serum from an uninfected cat (−) using recombinant FFV
the position of recombinant GST-TM protein, a commonly detected non-speciﬁc band (ns),
uninfected and (+) infected CRFK cells.a Western blot analysis (Fig. 3). Therefore, the prevalence of the FFV
infection in the German cats was calculated to be 39%. In a second,
smaller screen, another 143 sera were tested with the TM protein
based ELISA and consistent with the previous ﬁnding, 41% of them
were found to be positive for antibodies against the TM protein.
Epidemiology of FFV infection in German cats
Analyzing age, sex and castration status of the animals, a strong
correlation of the infection status with the age of the infected
animal was found (Fig. 4). Signiﬁcant differences in the infection
rate were found when very young and older cats were compared.
Whereas only 12.5% of the animals in the age of 0–1 year were FFV
positive, already 42% were infected in the group of 1–2 years
(P-value 0.001). The prevalence increased up to 75% for cats older than
12 years (Fig. 4A). Comparisonbetweenmale and female cats and their
castration status did not reveal any signiﬁcant differences (P=0.2,
P=0.3 and P=0.2, respectively, Fig. 4B) but some inﬂuence of the
castration status itself was measurable as an increase of FFV infections
in desexed animals (47% compared to 34% in non-desexed animals,
P-value 0.05, Fig. 4C).
Analysis of binding and neutralizing antibodies in the sera from infected
and immunized animals
To estimate the titers of TM binding antibodies in infected cats,
ELISAs using recombinant TM protein and serial sera dilutions wereA) In the top panel, ELISA results using the TM and Gag protein as antigens and the
ame sera using the recombinant TM protein (TM) or FFV-infected CRFK cells (CRFK) as
analyses. (B) Western blot results of representative serum 34713, a positive serum from
TM protein (left ﬁgure) and infected CRFK cells as antigen (right ﬁgure). Arrows indicate
and the characteristic 52 and 48 kDa Gag bands of FFV. In the right ﬁgure (−) indicates
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Fig. 4. Prevalence of FFV antibodies in dependence on the age of the animals. Animals were stratiﬁed by age, sex, castration status and the percentage of the sera positive in a TM
protein based ELISA, the total number of investigated animals and the P values are given.
336 M. Mühle et al. / Virology 412 (2011) 333–340performed. In average, titers of TM binding antibodies ranging from
0.8×102 to 2×104, medium 3×103, were measured (Table 1). To
detect neutralizing antibodies, ELISA positive sera were analyzed in
neutralization assays using FeFAB indicator cells and the FFV–FUV7
isolate and an improved 96 well protocol (see Material and methods).
In a panel of 90 sera tested, 13 were found to efﬁciently neutralize at
serum dilutions of 1/200 and higher. To conﬁrm the speciﬁcity of the
antibodies neutralizing FFV, an HIV-1 speciﬁc neutralization assay
using TZM-bl reporter cells and HIV-1 strain pNL-4.3 was performed
and no neutralization observed. When the sera from goat 348 and rats
immunized with the recombinant FFV TM protein were investigated,
all were strongly positive in ELISA and Western blot assays usingTable 1
Sera characterized by epitope mapping.
Serum Sex
of the animal
Age
of the animala
Antibody titre
ELISA Neutralization
FFV-TMb FFV–FUV7c
Goat 348 Female n.a. 1,0×106 b10
Rat 321-2 Female n.a. 5,0×105 b10
Rat 321-3 Female n.a. 1,4×106 b10
Cat 40202 Female 14 1280 b10
Cat 49499 Female 3 2560 b50
Cat 44093 Male 8 320 b50
Cat 56503 Male 6 1280 b50
Cat 30623 Female 13 20480 200
Cat 47831 Male 3 80 400
Cat 35051 Male n.a. 2560 N400
Cat 41746 Male 14 640 N400
a Age of animal in years, n.a. — no information available.
b Reciprocal serum dilution reacting positive (signal above 2×(OD490 nm of median
preimmune serum+3 standard deviations)) in an ELISA using FFV-TM.
c Reciprocal serum dilution resulting in more than 75% reduction of X-Gal staining in
a neutralization assay.recombinant TM protein with and without the GST fusion part with
titers in the range of 105 to 106, indicating that the antibodies are
directed against the TM protein. When the sera from immunized
animalswere analyzed for the presence of FFV-neutralizing antibodies
using the FeFAB indicator cell assay and FFV–FUV7, none of the sera
could prevent the infection.
Characterization of the antibody response by epitope mapping
In order to identify the epitopes recognized by the sera and
puriﬁed IgG from naturally FFV-infected cats and to compare them
with those recognized by the sera from goat 348 and the rats
immunized with the TM protein, overlapping peptides
corresponding to the ectodomain of the FFV TM protein were
used (Figs. 5A and B). This method identiﬁed several epitopes
(between three and seven), with the most obvious difference that
in the case of the sera from infected cats epitopes were missing in
the unusually prolonged central domain between NHR and CHR,
which contains eight cysteine residues (Fig. 5C) and is predicted to
be highly glycosylated (Wang and Mulligan, 1999). In contrast, the
sera from goat 348 and from rats immunized with the recombinant
FFV TM protein recognized epitopes mainly in this central region,
independent from the immunized species. Whereas all the sera
from the FFV infected cats recognized epitopes in the MPER and
the fusion peptide proximal region (FPPR), the sera from the
immunized did not recognize the epitopes in this region.
Discussion
Here we show that cats infected with FFV build up a strong
immune response against the viral TM protein and that this antigen
can be used to detect FFV infections in cats. In comparison with the
results of previously established assays using the group speciﬁc
antigen Gag and Bet, similar results were obtained when a large
337M. Mühle et al. / Virology 412 (2011) 333–340population of German cats was screened for FFV infection.
Approximately 39% of the animals were found infected. This
prevalence is in line with ﬁndings of other European areas
(Bandecchi et al., 1992; Daniels et al., 1999; Winkler et al., 1997,
1999; Romen et al., 2006). Epidemiological data showed that the
percentage of infected animals increases with age, and that
infection is predominantly acquired after the ﬁrst year of birth.
This time point correlates with sexual maturity, where cats start
roaming and get in contact with other cats, increasing the
probability of infection. Interestingly the number of animals infected
with FFV seemed higher among the desexed animals when
compared with the non-desexed. This may be explained by
toleration of straying of desexed rather than non-desexed cats by
the pet holder, or differences in social behavior caused by the
castration itself. Winkler et al. (1999) also reported a higher
number of positive animals among the desexed, but only among
young animals (less than 5 years) and not among older. In contrast
to what has been described for FIV, no differences in the infection
rate between male and female cats was found, suggesting a
different way of transmission such as prolonged intimate contact
instead of aggressive behavior (Winkler et al., 1999).
In order to diagnose a retroviral infection besides virus isolation
and PCR provirus detection, sensitive and speciﬁc antibody
detection methods may be used, since infections with retroviruses
are always accompanied by antibody production. Among the
immunological detection assays such as Western blot analysis,
immunoﬂuorescence and others, ELISAs have numerous advan-
tages: the assay is quick, sensitive, reproducible, cheap and easy to
use for screening large quantities of sera. Therefore an ELISA using
the TM protein as antigen was established. This assay gave similar
results compared with a well-characterized ELISA based on the Gag
protein (Romen et al., 2006). Upon screening 261 sera in both
assays, there were 11 sera with unclear results, nine detected only
the TM protein, two only the Gag protein. As in the case of the HIV
diagnostics, Western blot assays were performed to conﬁrm the
results, using either the recombinant TM protein or FFV-infected
CRFK cells expressing predominantly the Gag. Both assays showed
a good correlation with the ELISA results with exception of the
nine sera described (Fig. 3). Due to the lack of appropriate
additional material (e.g., blood or tissue samples) non-serological
analyses such as PCR or virus reisolation could not be performed.
Additional investigations should clarify such results. From our point
of view, it should be evaluated whether a combined assay using
both the Gag and the TM protein may be used for future screening.
Since serological testing for HIV-1 infection gave some false-
positive responses to HIV-Gag, strong criteria had been developed
requesting conﬁrmatory Western blot assays that show antibodies
against one of the envelope proteins on one hand and the Gag on
the other hand (Sayre et al., 1996).
Previous reports showed that antibodies against the surface
envelope protein of the foamyvirus FFV are rare in infected cats
(Romen et al., 2006). This is in contrast to the situation in animals
infected with orthoretroviruses, which produce high amounts of
antibodies against their surface envelope protein, e.g., gp120 in HIV-
1 infected individuals. The reasons for that discrepancy are still
unclear, one explanation may be the presence of non-infectious,
capsidless subviral Env-particles or the release of Env-Bet or Env-
Bel2 fusion proteins that lack the membrane-spanning domain of
TM in animals infected with FFV (Bodem et al., 1998; Pietschmann
et al., 2000; Shaw et al., 2003). These subviral particles or soluble
Env derivatives may act as decoys adsorbing antibodies speciﬁc for
the surface envelope protein, but not the antibodies against the TM
protein, which is hidden under the surface protein. In contrast to
foamy viruses, orthoretroviruses are unable to produce Env-
Particles, but they produce particles composed of Gag without Env
(Luttge and Freed, 2010).Different epitopes were identiﬁed when the sera obtained by
immunization with the ectodomain of the TM protein of FFV and the
sera from infected cats were analyzed (Fig. 5). The sera from
immunized animals (independent whether goat or rats) recognized
epitopes in the region characterized by potential glycosylation sites
(Wang and Mulligan, 1999; Luftenegger et al., 2005). This may be
explained by the fact that the administered antigen was the non-
glycosylated TM protein produced in bacteria. In contrast, the sera
from infected cats do not recognize these epitopes, but mainly the
epitopes outside the glycosylated region (Fig. 5C). These data indicate
that in the infected animals the epitopes may be hidden by
glycosylation (Lindemann and Goepfert, 2003; Luftenegger et al.,
2005) and antibodies against the protein backbone were not
produced. Since for the epitope mapping synthetic peptides and for
ELISA and Western blot analyses recombinant proteins produced in
bacteria were used, we cannot rule out the possibility that antibodies
against the glycosylated protein are generated. The sequences of the
epitopes recognized by the sera from infected animals are highly
conserved when different isolates were compared, suggesting that
there is no variability due to escape mutations.
The sera from goat 348 and the four rats immunized with the TM
protein did not inhibit FFV infection, indicating that the antigen in the
applied form did not induce neutralizing antibodies. We have
previously demonstrated that neutralizing antibodies were induced
by immunization with the recombinant ectodomain of the TM protein
p15E of the porcine endogenous retrovirus (PERV) (Fiebig et al.,
2003), the feline leukemia virus (FeLV) (Langhammer et al., 2005,
2006, 2010) and the Koala retrovirus (KoRV) (Fiebig et al., 2006) and
that main epitopes recognized were located in the FPPR and in the
MPER of the corresponding TM proteins. The epitopes located in the
MPER of the TM protein of these gammaretroviruses (FeLV, PERV, and
KoRV) resembled epitopes located in the MPER of the TM protein
gp41 of HIV-1 which are targeted by broadly neutralizing antibodies
such as 2F5 and 4E10. These antibodies had been isolated from HIV-1
infected patients and they prevent infection of up to 95% of primary
HIV-1 isolates. Furthermore, despite the evolutionary divergence
between HIV-1 and the gammaretroviruses, three identical amino
acids were found in the epitope of the antibody 4E10 neutralizing
HIV-1 and the epitopes recognized by the sera neutralizing PERV, FeLV
and KoRV (Fiebig et al., 2003; Langhammer et al., 2005, 2006,
unpublished data). However, immunizations with the ectodomain of
gp41 of HIV-1 did not result in neutralizing antibodies and no
epitopes located in the MPER were found (unpublished data). Results
similar to the ﬁndings obtained with HIV-1 were described here: the
sera from goat 348 and the rats immunized with the TM protein of FFV
were not neutralizing and did not recognize the epitopes close to the
membrane spanning domain. In contrast, the sera from cats naturally
infected with FFV were neutralizing and recognized the epitopes in
the MPER. Obviously the large size, the high complexity and the
strong glycosylation of the TM proteins of HIV-1 and FFV do not
support the conformations able to induce neutralizing antibodies
when immunizing with the entire ectodomain. Since the inﬂuence of
oligomerization, glycosylation and conformation on the ability of the
FFV TM protein to induce neutralizing antibodies is unknown, we ﬁrst
used the recombinant protein produced in the bacteria for reasons of
cheapness and ease of expression. It remains the subject of further
studies to clarify whether immunization with a glycosylated TM
protein produced in eukaryotic cells will result in the production of
neutralizing antibodies.
Materials and methods
Protein production
Expression vector pGEX-TMop-His containing the codon-opti-
mized ectodomain of the feline foamy virus FUV7 strain (Uniprot Acc.-
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339M. Mühle et al. / Virology 412 (2011) 333–340Nr. O56861, amino acids 563 - 944) was obtained by cloning of the
XhoI digested Pfx-PCR fragment ampliﬁed from the expression
plasmid pGEX-TMop using primers MM001 5′-aggatctggctctggatctgg-
tatcgagggaagggatctgaacgatcagaaactg-3′ and MM002 5′-atactcgagt-
tagtgatggtgatggtgatggtggtgcgcggtgccaaaaattccacc-3′ into SmaI/XhoI
digested pGEX-KG. A C-terminal 8×His tag was introduced using a
corresponding reverse primer. The construct was transformed into E.
coli BL21 and expression conditions were optimized. Induced cells
were pelleted by centrifugation and frozen at −20° until needed.
Puriﬁcation was performed by resuspending pellets in Buffer A (6 M
GuHCl, 100 mM NaCl, 100 mM NaH2PO4, 20 mM imidazol, 10 mM
TrisHCl, Complete EDTA free protease inhibitor, and pH 7.0) and
thoroughly soniﬁcation. After centrifugation (10.000×g, 20 min)
cleared lysate was loaded on a HisTrap FF Crude NiNTA-column
integrated in an automatic chromatography system (ÄktaExplorer
10 S, GE Healthcare), the column was washed intensively with buffer
B (8 M urea, 100 mM NaCl, 100 mM NaH2PO4, 80 mM imidazol,
10 mM TrisHCl, and pH 7.0) followed by a 20 column volume
refolding gradient to Buffer C (1 M urea, 100 mM NaCl, 100 mM
NaH2PO4, 80 mM imidazol, 10 mM TrisCL, 1 mM β-ME, and pH 7.0)
and elution with buffer D (1 M urea, 100 mMNaCl, 100 mMNaH2PO4,
500 mM imidazol, 10 mM TrisHCl, and pH 7.0). Protein concentration
was estimated bymeasuring absorption at 280 nm or SDS-PAGE using
a BSA standard dilution series.ELISA
Puriﬁed recombinant protein (100 μl/well) diluted in water at a
ﬁnal concentration of 20 ng/μl was adsorbed overnight at 37 °C in 96-
well plates. Plates were washed once with PBS-T (phosphate buffered
saline, 0.05% Tween 20) and blocked with blocking buffer (1% non-fat
dry milk in PBS-T). Sera (1:100 in blocking buffer) were added and
incubated for one hour at 37 °C. After washing HRP-conjugated anti-
cat IgG (Bethyl Laboratories, 1:3000) were added. Detection was
performed as described (Denner et al., 1994). The GST capture ELISA
to measure antibodies speciﬁc for Gag and Bet were performed as
described (Romen et al., 2006).Sera and immunoglobulins
The sera from household and street cats were obtained from
LABOKLIN GmbH (Hannover, Germany), a laboratory for clinical
diagnostics. All sera were collected between July and August 2009.
Goat #348 and four rats were immunized three times with 500 or
250 μg puriﬁed GST-TMop-His in oily adjuvans (1:1) i.m and s.c. in
a three week interval following internationally recognized guide-
lines under approval of the Lageso, Berlin, reference numbers
H0028/03 and H0201/02. IgGs were isolated from the sera using a
Protein G based puriﬁcation kit (Ab SpinTrap IgG Puriﬁcation Kit,
GE Healthcare) as recommended by the manufacturer.Western blot analysis
Western blot analyses using the TM protein (Tacke et al., 2001) or
FFV infected CRFK cells (Winkler et al., 1998) were performed as
described.Fig. 5. Epitope mapping of the sera from animals immunized with the TM protein of FFV and
The central box shows a membrane spotted with overlapping peptides corresponding to
development with secondary antibody as described in Materials and methods. The sequence
The sequence of the TM protein of FFV (accession number 056861) and sequences of the epito
the location of the fusion peptide (FP), the fusion peptide proximal region (FPPR), the memb
location of the predicted glycosylation sites (Y) and the cysteine residues (C) is indicated. In
and infected animals is shown.Neutralization assay
An indicator cell line based assay (Zemba et al., 2000) was
modiﬁed using 96 well plates and an ELISPOT reader. Brieﬂy, 2×104
FeFAB cells, were seeded into each well one day before infection and
supplied with 50 μl fresh DMEM containing 0,5 μg/μl G418 on the day
of the assay. 25 μl of each serum dilution (1:50, 1:100, 1:200 and
1:400) and 25 μl FFV containing supernatant (3×104 infectious
particles/ml) were incubated for 30 min at 37 °C, added to the cells
and incubated for two days. To test for antibodies neutralizing HIV-1,
2×104 TZM-bl cells and 25 μl HIV-1 pNL-4.3 (0.63×104 infectious
particles/ml) were used. To determine the number of infected cells,
medium was removed; cells were washed twice with PBS, ﬁxed for
10 min with 2% paraformaldehyde and after two additional washing
steps stainingwas performed using X-gal containing staining solution.
Blue colored cells were counted in an ELISPOT reader (AID, Strassberg,
Germany). Neutralization titers were expressed as serum dilutions
that showed more than 75% reduction of plaque forming units
compared to the infected control. All measurements were performed
in triplicates.
Epitope mapping
Pepspot libraries comprising the ectodomain of the FFV TMprotein
as 15-mer peptides overlapping by 13 amino acids were used to
identify epitopes in the described sera. Membranes were saturated for
at least two hours in TBS-T (Tris-buffered saline, pH 7.5, 0.05% Tween
20) containing 5% dry milk powder and then incubated with Protein G
puriﬁed IgGs (Ab Spin Trap, GE Healthcare) from goat (1:800), rat
(1:800) and cat sera (1:100), washed three times for 10 minwith TBS-
T and then incubated for 2 h with an appropriate peroxidase-
conjugated secondary antibody diluted 1:3,000. Binding was detected
using a chemiluminescence detection solution (ECL, Amersham
Pharmacia Biotech). Core epitopes were deﬁned as the centrally
shared amino acids of overlapping peptides recognized with identical
signal intensity.
Statistical analysis
To evaluate the statistical signiﬁcance between selected groups,
Pearson's Chi-Square test was used. P values of 0.05 and less were
considered signiﬁcant.
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